How to Get Evenity (Romosozumab) in California

What Is Evenity (Romosozumab) and Why Does It Matter for Californians With Osteoporosis?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. Blocking sclerostin lets the drug increase bone formation while also reducing bone breakdown, a dual mechanism that sets it apart from bisphosphonates and denosumab, which mainly slow bone breakdown. The FDA approved romosozumab under the brand name Evenity in 2019 for postmenopausal women at high risk of fracture, and has since expanded the approved population to include men with osteoporosis at high fracture risk 1 2.

The Trial Evidence Behind the Prescription

In the ARCH trial involving 4,093 postmenopausal women with osteoporosis and previous vertebral fracture, researchers evaluated sequential treatment with romosozumab and alendronate versus alendronate monotherapy. At 24 months, patients receiving romosozumab followed by alendronate demonstrated reduced incidence of both new vertebral fractures and hip fractures relative to alendronate monotherapy 3. However, romosozumab treatment was associated with an increased incidence of serious cardiovascular adverse events within the initial 12 months compared to alendronate treatment, prompting the drug's boxed warning 3.

The FRAME trial (N=7,180) found that 12 months of romosozumab substantially reduced new vertebral fractures compared with placebo 4. These two trials are the ones most commonly referenced in prior authorization reviews for this drug.

Who Typically Qualifies for Romosozumab in California?

The FDA label and the 2020 American Association of Clinical Endocrinology (AACE) osteoporosis guidelines describe the population most likely to meet prescribing and coverage criteria:

• A DXA T-score of -2.5 or below at the spine, femoral neck, or total hip
• A prior low-trauma vertebral or hip fracture, regardless of T-score
• A FRAX 10-year fracture probability high enough to be classified as very high risk
• Failure of, or intolerance to, prior bisphosphonate therapy

Medi-Cal and most California commercial plans require prior authorization and generally look for these same high-risk features, though exact criteria differ by plan and can change. Confirm current criteria with the specific plan rather than assuming any single set of numbers applies.

Step 1: Choose a Qualified Prescriber in California

California permits MDs, DOs, nurse practitioners holding an active furnishing license, and physician assistants working under a supervising physician to prescribe romosozumab. Telehealth prescribing is addressed under California Business and Professions Code Section 2290.5, which sets standards for synchronous audio-video encounters 6.

Telehealth vs. In-Person: What Actually Differs

A telehealth endocrinologist or rheumatologist licensed in California can review your DXA report, order pre-treatment labs, write the prescription, and submit prior authorization paperwork remotely. What cannot happen by telehealth is the injection itself. Romosozumab is a subcutaneous injection given by a healthcare professional; self-injection is not the labeled route of administration. You will still need a local clinic, rheumatology office, or infusion center for each monthly dose.

Finding a Prescriber in California

California has a large number of practicing endocrinologists and rheumatologists relative to many states, but demand at academic bone health centers can mean a longer wait for a first new-patient appointment. If a local specialist's next opening is weeks away, a telehealth consultation with a California-licensed endocrinologist or rheumatologist, followed by injections at a separate local clinic, is a reasonable way to start the workup sooner. Ask any telehealth platform directly about current appointment availability rather than relying on a fixed number, since scheduling changes often.

Step 2: Required Labs and Imaging Before Your First Dose

No romosozumab dose should be given before a baseline metabolic and imaging workup. The FDA label calls for correcting hypocalcemia before starting therapy 2. Most California insurance plans also require this documentation as part of prior authorization.

Laboratory Tests

Some prescribers also order a bone turnover marker panel (P1NP and CTX) at baseline. These markers are not required by the FDA label but a small study has suggested they can help track anabolic response over the first several months of treatment.

Imaging Requirements

A recent DXA scan is the standard documentation for prior authorization; many California payers and Medi-Cal want a scan performed within roughly the past two years, though the exact cutoff is plan-specific and should be confirmed. Vertebral fracture assessment (VFA) performed on the same DXA unit adds useful fracture information without additional radiation and is recommended in professional imaging guidance 8.

Step 3: Cardiovascular Screening and the Boxed Warning

Evenity carries an FDA boxed warning for cardiovascular risk. In the ARCH trial, serious cardiovascular adverse events were more common in the romosozumab group than the alendronate group during the 12-month active treatment phase 3. The FDA label states that romosozumab should not be started in patients who have had a myocardial infarction or stroke within the preceding 12 months 2.

What the Cardiovascular Screening Visit Covers

Your prescriber will typically document:

• Date of any prior heart attack, stroke, TIA, or unstable angina
• Current antiplatelet or anticoagulant therapy
• Uncontrolled hypertension worth addressing before starting
• Active atrial fibrillation with thromboembolic risk

The 2020 AACE guidelines advise against starting romosozumab within a year of a myocardial infarction or stroke and recommend assessing cardiovascular risk before prescribing, consistent with the FDA boxed warning. If you have significant cardiovascular history, your prescriber and a cardiologist should weigh the fracture-prevention benefit against the cardiovascular risk before you start.

A 12-lead ECG is not required by the label but may be ordered at the prescriber's discretion when the cardiac history is unclear.

Step 4: Prior Authorization in California

Prior authorization is required by nearly every California commercial payer and by Medi-Cal for romosozumab. Knowing what a reviewer typically looks for can shorten the back-and-forth.

Documentation Commonly Requested for California PA

• DXA report with T-scores at spine and hip
• A supporting diagnosis code, such as M80.00 (postmenopausal osteoporosis with current pathological fracture) or M81.0 (age-related osteoporosis without current pathological fracture)
• Cardiovascular clearance note confirming no MI or stroke in the prior 12 months
• Serum calcium result within normal range
• 25-OH vitamin D level
• Prior therapy history (bisphosphonates, denosumab, or teriparatide) if applicable
• Letter of medical necessity from the prescribing clinician

What Happens if PA Is Denied?

California health plans are required to provide a written denial with a clinical rationale, and members have a right to an internal appeal. Appeal documentation commonly includes a repeat DXA confirming a persistent low T-score, evidence of fracture progression on imaging, or documentation of bisphosphonate intolerance or non-response. If an internal appeal fails, the California Department of Managed Health Care accepts Independent Medical Review (IMR) applications, and IMR decisions bind the health plan 9. The exact statutory basis for denial and appeal rights can change; verify current requirements with DMHC or the plan's appeal notice rather than relying on a remembered bill number.

California Evenity Access Checklist: What's Stable vs. What You Must Verify Now

Facts about a drug's biology and trial evidence rarely change. Facts about which plan covers what, how long approval takes, and what you will pay change constantly. Use this checklist to separate the two before you or your care team act on anything in this guide.

Stable facts (clinical and federal, unlikely to change quickly)

Date-sensitive facts (verify before relying on them for a real decision)

If any claim in this article falls into the second table, treat it as a starting point for your own verification, not a guarantee.

Step 5: Filling the Prescription, Pharmacy and Specialty Distribution in California

Romosozumab is a specialty biologic distributed through specialty pharmacies rather than standard retail chains. Amgen operates a patient support program that connects patients with specialty pharmacy partners and, for eligible commercially insured patients, copay assistance. Contact the program through Amgen's current official Evenity website rather than a phone number that may go out of date.

Specialty Pharmacy Distribution

Specialty pharmacies commonly used for biologics like romosozumab, including Accredo, CVS Specialty, Walgreens Specialty Pharmacy, and Optum Specialty Pharmacy, are licensed to operate in California, though which one is used for a given patient depends on the insurance plan's network. Each pen requires refrigerated storage between 2°C and 8°C (36°F to 46°F) and must not be frozen. Shipment is coordinated to the administering clinic or physician's office rather than the patient's home, since a healthcare professional must give the injection.

503A Compounding Pharmacies and Romosozumab

Romosozumab is a complex monoclonal antibody made through recombinant DNA technology. California 503A compounding pharmacies are licensed for traditional patient-specific compounding, but a molecule of this complexity is not something 503A compounding is designed or authorized to reproduce. FDA guidance on drug compounding is clear that complex biologic products fall outside the scope of traditional compounding 10. Obtain romosozumab only as the branded Evenity product through a licensed specialty pharmacy.

Step 6: Receiving Your Monthly Injections in California

Each dose consists of two 105 mg subcutaneous injections (210 mg total), given consecutively in the abdomen, thigh, or upper arm by a healthcare professional 2. Both injections happen at the same monthly visit, for 12 consecutive months.

Where to Get Injected in California

• Rheumatology or endocrinology offices
• Bone health clinics at academic medical centers
• Infusion centers that handle subcutaneous biologics
• Primary care offices with staff trained in biologic administration

Plan to stay in the clinic for a short observation period after the injection given the low but real risk of hypocalcemia symptoms such as tingling or muscle cramps. If your baseline calcium or vitamin D was borderline, ask your prescriber whether an early follow-up calcium check makes sense for you specifically; this is an individualized decision your prescriber should make based on your labs, not a fixed rule for every patient.

What Happens After 12 Doses

The 12-dose course is the complete romosozumab treatment. The FDA label and AACE guidelines both call for transitioning to an antiresorptive agent after the course to preserve the bone gains. Common transition options include:

• Alendronate (oral bisphosphonate, generic available)
• Denosumab (Prolia, subcutaneous injection every 6 months)
• Zoledronic acid (intravenous infusion, typically annual)

Skipping transition therapy can lead to loss of the bone density gained during treatment, so this step should be planned before you finish your last romosozumab dose, not afterward.

Cost and Coverage in California

Commercial Insurance

Most California commercial plans place romosozumab on a high specialty formulary tier with prior authorization. Out-of-pocket costs without assistance can be substantial for a specialty-tier biologic and vary by plan design, deductible status, and whether a copay assistance program applies. Ask your specific plan for a current cost estimate, and ask the dispensing specialty pharmacy for a cash-price quote if you are uninsured, since neither figure is fixed.

Amgen's manufacturer support program may reduce out-of-pocket cost for eligible commercially insured patients; check current eligibility rules on Amgen's official site, since program terms change.

Medi-Cal Coverage

Medi-Cal covers romosozumab for qualifying severe postmenopausal osteoporosis with prior authorization. Managed care plans within Medi-Cal use their own PA forms but are expected to apply comparable clinical criteria. Confirm the current PA process and any policy reference number directly with Medi-Cal Rx or the specific managed care plan rather than an older cited policy number, since administrative policy numbers can be revised.

Medicare Part B vs. Part D

When administered by a healthcare professional in a clinical setting, romosozumab is typically billed under Medicare Part B rather than Part D 11. This matters because Part B cost-sharing (coinsurance after the deductible) works differently from Part D specialty-tier cost-sharing, and coverage determinations can vary by Medicare Administrative Contractor.

Monitoring During the 12-Month Course

The following monitoring pattern reflects FDA label safety information and general AACE practice guidance 2:

In the FRAME trial, romosozumab produced meaningfully greater lumbar spine and femoral neck bone density gains than placebo at 12 months 4. A repeat DXA at 12 months on your own scans, not a population average, is what should guide your individual transition plan.

Telehealth-Specific Workflow for California Patients

For patients who want to start the process without a long wait for a specialist visit, the telehealth pathway generally looks like this:

1. Schedule a video visit with a California-licensed endocrinologist, rheumatologist, or bone health specialist.
2. Have your most recent DXA report and any prior fracture imaging available before the visit, or ask the clinic to help retrieve records.
3. The clinician reviews your cardiovascular history, orders any missing labs, and confirms eligibility.
4. The prescription and PA paperwork are typically submitted electronically shortly after the visit.
5. You identify a local clinic or rheumatology office willing to administer the injections, and the specialty pharmacy ships the medication there.
6. The first injection can happen once labs are back and PA is approved; ask your care team for a current, plan-specific timeline rather than assuming a fixed number of weeks.

California's telehealth parity law (AB 744) addresses reimbursement for telehealth medication management visits by many commercial payers 12. Confirm how your specific plan applies parity rules, since payer implementation can vary.

Special Populations and California-Specific Considerations

Men With Osteoporosis

The FDA has also approved romosozumab for men with osteoporosis at high risk of fracture, based on the BRIDGE trial (N=245), which showed a meaningfully greater increase in lumbar spine bone density at 12 months versus placebo 13. Medi-Cal PA criteria for men generally mirror those applied to postmenopausal women, though documentation of a secondary cause of osteoporosis, such as hypogonadism or chronic glucocorticoid use, can strengthen a PA submission.

Glucocorticoid-Induced Osteoporosis

Patients on long-term glucocorticoid therapy face accelerated bone loss. The 2022 American College of Rheumatology guideline for glucocorticoid-induced osteoporosis lists romosozumab as a preferred anabolic option for patients at very high fracture risk 14. If you have lupus, rheumatoid arthritis, or inflammatory bowel disease and are on chronic steroids, ask your rheumatologist whether romosozumab should be considered earlier in your treatment plan given your fracture risk.

Prior Denosumab Use and Rebound Risk

Patients transitioning from denosumab (Prolia) require careful sequencing. Stopping denosumab without prompt follow-up therapy can cause rebound vertebral fractures in some patients, and starting romosozumab directly after denosumab does not fully eliminate this risk 15. A common approach is to begin romosozumab at the time the next denosumab dose would have been due, then transition to a bisphosphonate after the romosozumab course. This sequencing decision should be made with your prescriber, not from a general guide.